According to our new research study on "Drug Delivery Devices Contract Manufacturing Market Forecast to 2031 -Global Analysis - by Device Type, Service Type, and Geography," the market is anticipated to grow from US$ 8.24 billion in 2025 to US$ 21.72 billion by 2034, with a CAGR of 11.5% during 2026-2034.

The drug delivery devices contract manufacturing market growth is attributed to the increasing prevalence of chronic diseases, technological advancements and innovation, and cost efficiencies through outsourcing.

Outsourcing the design, development and production of drug delivery devices to Contract Development and Manufacturing Organizations (CDMOs) that specialize in these areas means that pharmaceutical and biotechnology companies can concentrate on their core competencies of drug development, research and development and commercialization while benefiting from the experience, expertise, technological capabilities and scale provided by third party manufacturers who manage complete end-to-end production processes. These include fabrication of components, assembly, quality assurance, testing, regulatory compliance, and packaging. Adoption of AI and digital technologies in manufacturing, emphasis on sustainable and eco-friendly manufacturing practices, and the rise of personalized and patient-centric delivery systems are expected to emerge as major drug delivery devices contract manufacturing market trends in the coming years.

The drug delivery devices contract manufacturing market in North America is segmented into the US, Canada, and Mexico. The North America drug delivery devices contract manufacturing market is expanding as the region hosts numerous facilities, with the US alone featuring over 400 specialized sites focused on class II and III devices, emphasizing precision engineering and regulatory compliance. The US holds the largest market share, followed by Canada.

In the United States alone, there are more than 400 specialized facilities that specialize in producing class II and class III medical devices with a focus on engineering precision, regulatory compliance, and developing new technologies for injectables, inhalers and transdermal delivery systems. Leading companies such as Catalent operate multiple facilities for assembling autoinjectors and pen injectors. Integer Holdings Corporation provides the assembly for infusion pumps, allowing them to quickly ramp up production to meet the needs of customers who require high volumes. According to recently released data from the Centers for Disease Control and Prevention (CDC), outsourcing of cardiovascular and orthopaedic delivery devices is projected to grow at an annualized rate of 11.4% until 2020, primarily due to increased rates of diabetes amongst adult Americans (34+ million). The total number of people working in medical device manufacturing exceeds 1 million; improvements in automation have led to a reduction of the defect rate by 20%.

Disruption in the Supply Chain resulted in a 15 % Impact to Time to Market caused by methods employed by the Case for Quality (CfQ) initiative through the FDA - Case for Quality is focused on improving quality practices and building partnerships. The Merger between Kindeva Drug Delivery and Meridian Medical Technologies and their merger in 2025 reflects the increased capacity to create parenteral and inhalation products. Conversely, Regeneron continues to expand its business activities based on Gene Therapy Vector development and Continuous Glucose Monitor (CGM) development initiatives. Additionally, our relationships with Apiject allow us to scale our Blow-Fill-Seal units at our Brookhaven facilities while simultaneously growing our line of sterile dosage forms and HCP CCC's. Our Sector has many attributes, including Skilled Workforce, Research & Development Incentives and over 50% of our Facilities utilize Renewable Energy Sources, which results in reducing our carbon footprint by 30%. Subtitle Technologies, along with Strategic Investments, create a unique environment for Advanced Drug Delivery Outsourcing. Therefore, the United States is well-positioned to be a Global Leader in Advanced Drug Delivery Outsourcing due to its advanced Technology and Strategic Investments.

The US Food and Drug Administration, World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization) are among the primary and secondary sources referred to while preparing the drug delivery devices contract manufacturing market report.